Source: Annual Congress 2004 - Infectious pneumonia and related diseases including tuberculosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
T. A. Fedorova, R. V. Klochko, V. B. Rudikov, P. K. Yablonsky (St Petersburg, Russia). Intravenous steroids in the treatment of community-acquired pneumonia (CAP). Eur Respir J 2004; 24: Suppl. 48, 437

Member's Comments

No comment yet.

Related content which might interest you: Use of ceftriaxone/sulbactame for treatment of mild-to-severe community-acquired pneumonia (CAP) Source: Annual Congress 2009 - Treatment of airways disease Year: 2009 Are corticosteroids useful in community-acquired pneumonia? Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia Year: 2006 Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia Source: Eur Respir J 2010; 36: 128-134 Year: 2010 Efficacy of corticosteroids in hospital treated community-acquired pneumonia Source: Annual Congress 2012 - Clinical management of lung diseases: from bronchi to pleura Year: 2012 Atypical agents of community-acquired pneumonia (CAP) Source: Eur Respir J 2003; 22: Suppl. 45, 485s Year: 2003 Oral antibiotics prior to hospitalisation for community-acquired pneumonia Source: Eur Respir J 2008; 31: 478-479 Year: 2008 Timing of antibiotic administration and outcomes for patients with community-acquired pneumonia (CAP). NAC-CV Study Source: Eur Respir J 2006; 28: Suppl. 50, 349s Year: 2006 Analysis of therapy of community-acquired pneumonia (CAP) at the COPD patients Source: Annual Congress 2011 - COPD management Year: 2011 Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients Source: Eur Respir J 2015; 45: 463-472 Year: 2015 Antibiotic usage analysis for community-acquired pneumonia (CAP) treatment Source: Annual Congress 2009 - Pulmonary infections Year: 2009 Fluoroquinolone versus β-lactam plus macrolide in patients hospitalized with community-acquired pneumonia (CAP) Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia Year: 2008 Low-dose corticosteroids during severe community-acquired pneumonia: end of the story Source: Eur Respir J 2015; 45: 305-307 Year: 2015 Adjunctive systemic corticosteroid treatment in hospitalized patients with community-acquired pneumonia Source: Annual Congress 2012 - Anti-infective treatment and resistance in respiratory infections Year: 2012 Corticosteroids and community-acquired pneumonia Source: Annual Congress 2007 - Corticosteroids and respiratory failure Year: 2007 Systemic corticosteroid for treating severe community-acquired pneumonia Source: International Congress 2015 – Advances in pneumonia management, COPD therapy and lung nodule evaluation Year: 2015 Antipyretic effect of dexamethasone in community-acquired pneumonia Source: Eur Respir J 2015; 46: 570-573 Year: 2015 Pharmacokinetic optimisation of β-lactams for the treatment of ventilator-associated pneumonia Source: Eur Respir Rev 2007; 16: 45-49 Year: 2007 Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with CAP Source: Eur Respir J 2013; 41: 123-130 Year: 2013 Combination versus monotherapy for nosocomial pneumonia Source: Eur Respir Rev 2007; 16: 50-55 Year: 2007